With box warnings

Without box warnings

Branded

Generic

2 results

mekinist
(trametinib)
Novartis Pharmaceuticals Corporation
Usage: MEKINIST is indicated for treating unresectable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC), locally advanced or metastatic anaplastic thyroid cancer, unresectable or metastatic solid tumors, and low-grade glioma with BRAF V600E/K mutations, in combination with dabrafenib, as per FDA-approved tests.
retevmo
(selpercatinib)
Eli Lilly and Company
Usage: RETEVMO is indicated for adult and pediatric patients aged 2 years and older with RET fusion-positive non-small cell lung cancer, RET-mutant advanced medullary thyroid cancer, RET fusion-positive advanced thyroid cancer, and RET fusion-positive solid tumors that require systemic therapy, following specific testing.

Medications for Solid Neoplasm

mekinist